Table 7.

The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination golimumab and methotrexate and golimumab monotherapy compared to methotrexate monotherapy

	GO-BEFORE28			GO-FORWARD27
	MTX + placebo n = 160	Golimumab 100 mg 4 weekly n = 159	MTX + golimumab 50 mg 4 weekly n = 159	MTX + placebo n = 133	Golimumab 100 mg 4 weekly n = 133	MTX + golimumab 50 mg 4 weekly n = 89
At 24 wks (%):
ACR 20	49	52	62b	28	35	60a
ACR 50	29	33	40b	14	20	37a
ACR 70				5	11b	20a

Notes:

^aP < 0.001 compared to placebo group;

^bP < 0.05 compared to placebo group.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.